3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Motor Activity
6
Polycystic Ovary Syndrome
2
Obesity
2
Diabetes Mellitus
2
Stroke
1
Sedentary Behavior
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Osteoporosis
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lung Neoplasms
1
Limb-girdle muscular dystrophy, type 2C
1
Leukemia, Myeloid, Acute
1
Kidney Diseases
1
Insulin Resistance
1
Hypertension
1
Heart Failure
1
Frailty
1
Endometrial Neoplasms
1
Diabetes Mellitus, Type 2
1
Cardiovascular Diseases
1
Breast Neoplasms
1
Body Weight
1
Arthritis
1
Interventions
pembrolizumab
37
Paclitaxel
36
Carboplatin
31
Cyclophosphamide
22
Albumin-Bound Paclitaxel
20
atezolizumab
16
130-nm albumin-bound paclitaxel
16
Taxes
15
Doxorubicin
15
Cisplatin
13
Capecitabine
13
Nivolumab
10
Docetaxel
8
olaparib
7
Gemcitabine
6
Everolimus
6
talazoparib
5
durvalumab
5
Magnetic Resonance Spectroscopy
5
Biopsy
5
Bevacizumab
5
veliparib
4
spartalizumab
4
sacituzumab govitecan
4
pegfilgrastim
4
liposomal doxorubicin
4
eribulin
4
Specimen Handling
4
Immunoglobulin G
4
trilaciclib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Triple Negative Breast Neoplasms
×
Resistance Training
×
Clear all
No trials found.